Darinaparsin to be Commercialized in Japan
Published By : 21 Jan 2015 | Published By : QYRESEARCH
Solasia Pharma KK is a medical firm established with the motive to hasten the patient access to unique oncology therapies in the West. Meiji Seika Pharma Co. has formed a license agreement with Solasia for the commercialization and development of intravenous formulation in Japan, where it is known as darinaparsin.
The former firm is currently in its initial phase of studying darinaparsin in South Korea and Japan. The studies are performed in an effort to treat patients with relapsed and refractory peripheral T Cell lymphoma.
An exclusive worldwide license has been obtained by Solasia to develop and commercialize darinaparsin through Ziopharm Oncology. The firm is at present, conducting clinical trials in parts of Asia, particularly in Japan.
According to the agreement struck, Solasia will keep making developments on darinaparsin for patients with refractory and relapsed peripheral T Cell lymphoma. Upon completion of developments, the company will initiate a Phase II which involves a pan-Asia study. After the study, the firm will attempt to gain regulatory approval in Japan. Upon approval, Meiji will commercialize, distribute, and promote all aspects of darinaparsin for peripheral T Cell lymphoma all over Japan.
In addition to the primary factor of agreement, Meiji has also gathered the rights to commercialize and develop darinaparsin for symptoms outside of relapsed and refractory PTCL. The firm has also gained the option to produce an intravenous formulation of the treatment along with primary negotiation rights when it comes to the formulations outside of the intravenous one of darinaparsin.
Darinaparsin is an agent that is mitochondrial targeted. It is currently being developed as a cure solution for numerous hematologic and solid cancers.